Ucb 34714 (DrugBank: -)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
149 | Hemiconvulsion hemiplegia epilepsy syndrome | 1 |
309 | Progressive myoclonus epilepsy | 6 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-JapicCTI-173615 | 22/8/2017 | 15/06/2017 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization | Epilepsy and epilepsy syndrome | Intervention name : ucb 34714 INN of the intervention : Brivaracetam Dosage And administration of the intervention : Oral administration Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | NULL | recruiting | 16 | 80 | BOTH | 444 | Phase 3 | Japan, Asia except Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2006-000169-12-NL (EUCTR) | 27/12/2006 | 28/09/2006 | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. | Patients with genetically ascertained Unverricht-Lundborg disease (ULD). MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease | Product Name: Brivaracetam Product Code: ucb 34714 INN or Proposed INN: brivaracetam Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide Product Name: Brivaracetam Product Code: ucb 34714 INN or Proposed INN: brivaracetam Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | UCB S.A. | NULL | Not Recruiting | Female: yes Male: yes | 42 | Finland;Netherlands;France;Italy;Sweden | |||
2 | EUCTR2006-001536-46-FI (EUCTR) | 21/11/2006 | 10/10/2006 | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trial | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trial | Patients with genetically ascertained Unverricht-Lundborg disease (ULD). MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease | Product Name: Brivaracetam Product Code: ucb 34714 Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide Product Name: Brivaracetam Product Code: ucb 34714 Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide Product Name: Brivaracetam Product Code: ucb 34714 Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide | UCB S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Finland;France | |||
3 | EUCTR2006-001536-46-FR (EUCTR) | 14/11/2006 | 25/08/2006 | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trial | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trial | Patients with genetically ascertained Unverricht-Lundborg disease (ULD). MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease | Product Name: Brivaracetam Product Code: ucb 34714 Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide Product Name: Brivaracetam Product Code: ucb 34714 Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide Product Name: Brivaracetam Product Code: ucb 34714 Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide | UCB S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Finland;France | |||
4 | EUCTR2006-000169-12-FR (EUCTR) | 03/11/2006 | 25/08/2006 | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. | Patients with genetically ascertained Unverricht-Lundborg disease (ULD). MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease | Product Name: Brivaracetam Product Code: ucb 34714 INN or Proposed INN: brivaracetam Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide Product Name: Brivaracetam Product Code: ucb 34714 INN or Proposed INN: brivaracetam Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | UCB S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Finland;Netherlands;France;Italy;Sweden | |||
5 | EUCTR2006-000169-12-SE (EUCTR) | 06/10/2006 | 07/08/2006 | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. | Patients with genetically ascertained Unverricht-Lundborg disease (ULD). MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease | Product Name: Brivaracetam Product Code: ucb 34714 INN or Proposed INN: brivaracetam Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide Product Name: Brivaracetam Product Code: ucb 34714 INN or Proposed INN: brivaracetam Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | UCB Pharma S.A. | NULL | Not Recruiting | Female: yes Male: yes | 45 | Finland;Netherlands;France;Italy;Sweden | |||
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | EUCTR2006-000169-12-FI (EUCTR) | 28/09/2006 | 31/07/2006 | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. | A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. | Patients with genetically ascertained Unverricht-Lundborg disease (ULD). MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease | Product Name: Brivaracetam Product Code: ucb 34714 INN or Proposed INN: brivaracetam Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide Product Name: Brivaracetam Product Code: ucb 34714 INN or Proposed INN: brivaracetam Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | UCB S.A. | NULL | Not Recruiting | Female: yes Male: yes | 42 | Finland;Netherlands;France;Italy;Sweden |